9
By Cody Tranbarger, Entrepreneur In Residence at Atlas Venture, as part of the From The Trenches feature of LifeSciVC
What if the biggest obstacle to the next generation of I&I therapeutics isn’t finding better targets — but accepting that one target was never going to be enough? It’s a question the industry spent twenty years not asking. The Humira playbook was too lucrative, the growth too easy, and the incentives too misaligned to seriously reckon with biological reality. Now, with the single-target era approaching exhaustion and an efficacy ceiling that fifty antibodies have failed to crack, biopharma has finally embraced…